• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Bangalore, June 24 Bal Pharma Ltd is focussing on a four-fold revenue growth to Rs 300 crore by the end of 2010, according to its Managing Director, Mr Shailesh Siroya.

Its new manufacturing plant in Uttarkhand is nearing completion and conforms to USFDA (US Food and Drug Administration) and the UK MCHRA guidelines. Its active pharma ingredients (API) plant at Bommasandra in Bangalore has been approved by the Australian regulator TGA (Therapeutic Goods Administration).

For the year ended March 31, 2008, net sales income of Rs 90.35 crore was up 18.6 per cent year-on-year.

More Stories on : New Projects | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
BPCL to amend clauses

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line